Home / Health / J&J Drug Obliterates Prostate Tumors in Early Trial
J&J Drug Obliterates Prostate Tumors in Early Trial
26 Oct
Summary
- Experimental J&J drug showed tumors disappearing or shrinking.
- 77% of patients saw PSA levels drop by at least 50%.
- 75% of measurable tumors responded completely or partially.
Johnson & Johnson announced a significant breakthrough on October 24, 2026, with its experimental oral prostate cancer drug, JNJ-6143. In an early-stage clinical trial, the drug demonstrated remarkable efficacy, causing tumors to disappear or shrink in patients battling advanced prostate cancer. This promising treatment, acquired through J&J's purchase of Halda Therapeutics, targets cancer cells by interfering with essential survival proteins.
The trial results, presented at the European Society for Medical Oncology Congress, are highly encouraging. Seventy-seven percent of 31 evaluable patients receiving a 50-milligram dose saw their PSA levels, a key marker for prostate cancer, fall by at least 50%. Furthermore, nearly half of these patients experienced a PSA reduction of 90% or more. For those with measurable tumors, imaging confirmed a complete or partial response in 75% of cases.
While the drug shows great potential, common side effects included nausea and elevated cholesterol and triglyceride levels. One patient discontinued treatment due to adverse effects. Analysts suggest JNJ-6143 could be a game-changer for prostate cancer treatment and bolster J&J's oncology pipeline with its novel mechanism of action.
